Table IV:

Changes in Pharmacokinetic Parameters (Expressed as Ratios of Interaction / Control) for Orally Dosed Apixaban (Victim) and Rifampin (Perpetrator)

Victim Drug:	Perpetrator Drug:	Enzyme or Transporter	Population	$\frac{{\mathit{M}\mathit{A}\mathit{T}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{M}\mathit{A}\mathit{T}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{t}}_{\mathit{m}\mathit{a}\mathit{x}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{t}}_{\mathit{m}\mathit{a}\mathit{x}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{M}\mathit{R}\mathit{T}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{M}\mathit{R}\mathit{T}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{t}}_{1/2,\mathit{z}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{t}}_{1/2,\mathit{z}}^{\mathit{C}\mathit{o}\mathit{n}}}$	Percent AUC Extrapolation (DDI/Con)	Reference
Apixaban (Single Dose)	Rifampin (Multiple Dose)	CYP3A4 P-gp (Induction)	Healthy Subjects (n=20)a	0.92b	1.00	0.48	2.14	1.42b	0.65b	1.03	10%/9%	(25)

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: AUC, area under the curve; Con, control; CL/F, apparent clearance; CYP, cytochrome P450; DDI, drug-drug interaction; MAT, mean absorption time; MRT, mean residence time; P-gp, P-glycoprotein; t_max, time to maximal concentration; t_1/2,z, terminal half-life; V_ss/F, apparent volume of distribution at steady state

^aInteraction phase was n=18

^bRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental and/or compartmental analysis where single dose MRT was calculated using Eq. 5